Open AccessOccult hepatitis C virus infection in patients with malignant lymphoproliferative disorders
Author(s) -
Abeya A Lotfi,
Asmaa Elhassan Mohamed,
Nahela Ahmed Shalaby,
Deena Samir Eissa,
Ehab El-Dabaa,
Ayman M Sallam,
Mahmoud M. Kamel,
Hisham Abdelaziz,
Amal M. Elafifi,
Ahmed S. AbdelMoneim
Publication year - 2020
Publication title -
international journal of immunopathology and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.724
H-Index - 53
eISSN - 2058-7384
pISSN - 0394-6320
DOI - 10.1177/2058738420961202
Subject(s) - lymphoproliferative disorders , medicine , occult , hepatitis c virus , immunology , hepatitis c , ribavirin , lymphoproliferative response , viremia , virus , lymphoma , peripheral blood mononuclear cell , pathology , biology , biochemistry , alternative medicine , in vitro
Despite the link between HCV and malignant lymphoproliferative disorders has been established, the association between occult hepatitis C virus infection and malignant lymphoproliferative disorders remains obscure. The present study intended to identify the possible association between occult HCV infection and malignant lymphoproliferative disorders. Newly diagnosed patients with LPDs were screened for the presence of HCV-RNA in both plasma and PBMCs. PBMCs of the subjects were also, examined by transmission and immuno-electron microscopy. LPD patients showed a high percentage of HCV infection (71.9%): OCI-HCV (37.5%) and HCV (34.38%). Meanwhile, 28.13% of LPD patients did not show any evidence of HCV infection. Ultrastructural examination of PBMCs revealed the presence of intracytoplasmic vacuoles enclosing viral like particles, which were less prominent in occult HCV patients. The possibility of occult HCV should be considered in patients with LPDs which can be helpful in the management of the treatment protocol in order to set up a balance between the control of the tumor progression and minimizing post chemotherapy complications related to HCV infection.